Scholarlink

Purpose of Review <p>This review explores the rationale and available evidence behind incretin-based therapies for metabolic dysfunction-associated steatotic disease (MASLD) and metabolic-associated steatohepatitis (MASH), focusing on glucagon-like peptide 1 (GLP-1) and glucagon (GCG) receptor dual agonists (GLP-1/GCG RA’s).</p> Recent Findings <p>MASLD is the most prevalent chronic liver disease globally, with its more severe form, MASH, emerging as the leading cause of liver transplantation and hepatocellular carcinoma. However, cardiovascular disease remains the primary cause of mortality in this population. While there is no approved treatment for MASLD in Europe yet, incretin-based therapies are rising as promising option acting at both cardiovascular and hepatic level.</p> Summary <p>GLP-1/GCG RA’s have consistently shown a reduction in liver fat content independent of weight loss, positioning them as a promising treatment for MASLD and MASH. However, their approval will depend on histological and clinical outcomes, which rely on the results of ongoing Phase II and III trials.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

GLP-1 and Glucagon Receptor Dual Agonists in the Management of Metabolic Dysfunction-associated Steatotic Disease (MASLD)

  • 期刊论文

  • 发表日期：

    2025年5月30日

查看全文
  • Laura Pagès,
  • Aina Martí-Carretero,
  • Diego Rojo,
  • Clara Sabiote,
  • Farnaz Faninam,
  • Sophia C. Parks,
  • María Martínez-Gómez,
  • M Serra Cusidó,
  • Neda Akhlaghi,
  • Sergio Muñoz-Martínez,
  • Alba Jiménez-Masip,
  • Juan M. Pericàs

摘要

Purpose of Review

This review explores the rationale and available evidence behind incretin-based therapies for metabolic dysfunction-associated steatotic disease (MASLD) and metabolic-associated steatohepatitis (MASH), focusing on glucagon-like peptide 1 (GLP-1) and glucagon (GCG) receptor dual agonists (GLP-1/GCG RA’s).

Recent Findings

MASLD is the most prevalent chronic liver disease globally, with its more severe form, MASH, emerging as the leading cause of liver transplantation and hepatocellular carcinoma. However, cardiovascular disease remains the primary cause of mortality in this population. While there is no approved treatment for MASLD in Europe yet, incretin-based therapies are rising as promising option acting at both cardiovascular and hepatic level.

Summary

GLP-1/GCG RA’s have consistently shown a reduction in liver fat content independent of weight loss, positioning them as a promising treatment for MASLD and MASH. However, their approval will depend on histological and clinical outcomes, which rely on the results of ongoing Phase II and III trials.